Year: 2026

TORONTO, March 04, 2026 (GLOBE NEWSWIRE) — George Weston Limited (TSX: WN) (“GWL” or the “Company”) today announced its consolidated unaudited results for the 13 weeks ended December 31, 2025(2). GWL’s 2025 Annual Report includes the Company’s audited annual consolidated financial statements and Management’s Discussion and Analysis (“MD&A”) for the fiscal year ended December 31, 2025. The 2025 Annual Report has been filed on SEDAR+ and is available at www.sedarplus.ca and in the Investor Centre section of the Company’s website at www.weston.ca. As a result of the Company’s reporting calendar, the fourth quarter and full year 2025 include an extra week of operations (“the 13th week” or “the 53rd week”)(1) compared to the fourth quarter and full year 2024. “2025 marked another strong year for George Weston as Loblaw gained...

Exceeds Top End of Fiscal 2026 Revenue Outlook and Reports Record Q4 ResultsOperational Excellence Drives Record Free Cash FlowCompletes Strategic Acquisition of Power Solutions Accelerating Entry into High-Growth Data Center MarketFiscal 2027 Outlook Reflects Continued Organic Contract Revenue Growth and Adjusted EBITDA Margin Expansion Fourth Quarter Highlights(All metrics compared to the fourth quarter of fiscal 2025)Contract revenues of $1.458 billion(*) increased 34.4%, or 16.6% organically Net income of $16.3 million, or $0.55 per common share diluted Adjusted Net Income of $60.5 million(*), or $2.03(*) per common share diluted Adjusted EBITDA of $162.4 million(*), or 11.1% of contract revenues Operating cash flow of $419.0 million(*) Total backlog of $9.542 billion(*) Completed acquisition of Power Solutions, LLC on December 23,...

        – Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Campbell appointed Chief Commercial Officer to lead launch strategy and readiness for DURAVYU – – Over $300 million of cash and investments on December 31, 2025, providing runway into Q4 2027 – WATERTOWN, Mass., March 04, 2026 (GLOBE NEWSWIRE) — EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2025, and highlighted recent corporate developments. “Following a year of exceptional execution across our pivotal DURAVYU...

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Announced expansion of heme program with FDA clearance of TSC-102-A01 and TSC-102-A03 targeting CD45, in patients with HLA types A*01:01 and A*03:01 Cash and cash equivalents continue to fund operations into the second half of 2027 WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) —  TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three...

CALGARY, Alberta, March 04, 2026 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce its financial and operating results for the three- and twelve-month periods ended December 31, 2025, as well as the results of its independent reserves assessment as at December 31, 2025. Additionally, the Company declares its Q1 2026 regular dividend of C$0.385 per share and provides an operational update. All amounts herein are in United States dollars (“USD”) unless otherwise stated. Key HighlightsGenerated annual funds flow provided by operations (“FFO”)(1) of $455 million and free funds flow(2) of $145 million in 2025. Increased both PDP and 1P reserves per share by 4% and 2P reserves per share by 8%, compared to 2024(3). Strong PDP, 1P, and 2P reserves replacement at 106%, 106%,...

On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2025, and provided a corporate update. “2025 was a productive year for Cellectar, marked by disciplined execution across our pipeline and meaningful clinical,...